FFA
SNDX icon

Farther Finance Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Farther Finance Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.37K Sell
339
-87
-20% -$1.76K ﹤0.01% 4872
2026
Q2 		$9.31K Sell
426
-152
-26% -$3.16K ﹤0.01% 4466
2026
Q1 		$13.8K Buy
578
+37
+7% +$804 ﹤0.01% 3906
2025
Q4 		$11.4K Buy
541
+504
+1,362% +$8.79K ﹤0.01% 3829
2025
Q3 		$569 Buy
37
+14
+61% +$183 ﹤0.01% 4508
2025
Q2 		$215 Sell
23
-48
-68% -$528 ﹤0.01% 4194
2025
Q1 		$853 Sell
71
-86
-55% -$1.21K ﹤0.01% 3662
2024
Q4 		$2.08K Buy
157
+16
+11% +$274 ﹤0.01% 2985
2024
Q3 		$2.71K Buy
141
+11
+8% +$227 ﹤0.01% 2881
2024
Q2 		$2.8K Buy
130
+70
+117% +$1.47K ﹤0.01% 2651
2024
Q1 		$1.43K Hold
60
– – ﹤0.01% 2636
2023
Q4 		$1.3K Buy
+60
New +$922 ﹤0.01% 2626

Other funds holding SNDX

PRTG
Post Resch Tallon Group Pittsford, New York $146M AUM 18.19% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Farther Finance Advisors's SNDX Position: Q3 2026 in Review

Farther Finance Advisors reduced its Syndax Pharmaceuticals (SNDX) stake by 20% in Q3 2026, selling an estimated $1.76K and leaving 339 shares worth $6.37K. The position accounts for ﹤0.01% of the portfolio, ranked #4872.

Farther Finance Advisors first reported a position in SNDX in Q4 2023 and has held it in 12 quarters since. The position peaked at $13.8K in Q1 2026. 5 funds tracked by Wall St. Rank hold SNDX as of Q3 2026.

  • Farther Finance Advisors held 339 shares of Syndax Pharmaceuticals worth $6.37K as of Q3 2026.
  • Farther Finance Advisors sold 87 Syndax Pharmaceuticals shares in Q3 2026, an estimated $1.76K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #4872 holding.
  • Farther Finance Advisors first reported a position in Syndax Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • Farther Finance Advisors's Syndax Pharmaceuticals position peaked at $13.8K in Q1 2026.
  • 5 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.